Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell 2Lymphoma 2Triple Negative Breast Neoplasms 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Hodgkin Disease 1Hematologic Diseases 1Ganglioneuroblastoma 1Burkitt Lymphoma 1

Interventions

zanubrutinib 1ruxolitinib 1pirtobrutinib 1idecabtagene vicleucel 1ibrutinib 1fludarabine 1acalabrutinib 1Leukapheresis 1Lenalidomide 1Cyclophosphamide 1CPI-0610 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × Leukapheresis × 30 days × Clear all
NCT05032820 2026-05-19

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Medical College of Wisconsin

Phase 2 Completed
40 enrolled 32 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡